Development, management, and resolution of biliary complications after living and deceased donor liver transplantation: A report from the adult‐to‐adult living donor liver transplantation cohort study consortium

Michael A. Zimmerman, Talia Baker, Nathan P. Goodrich, Chris Freise, Johnny C. Hong, Sean Kumer, Peter Abt, Adrian H. Cotterell, Benjamin Samstein, James E. Everhart, Robert M. Merion – 11 March 2013 – Adult recipients of living donor liver transplantation (LDLT) have a higher incidence of biliary complications than recipients of deceased donor liver transplantation (DDLT). Our objective was to define the intensity of the interventions and the time to resolution after the diagnosis of biliary complications after liver transplantation.

Hepatitis B virus inhibits liver regeneration via epigenetic regulation of urokinase‐type plasminogen activator

Eun‐Sook Park, Yong Kwang Park, Chan Young Shin, Seung Hwa Park, Sung Hyun Ahn, Doo Hyun Kim, Keo‐Heun Lim, So Young Kwon, Kwang Pyo Kim, Sung‐Il Yang, Baik L. Seong, Kyun‐Hwan Kim – 8 March 2013 – Liver regeneration after liver damage caused by toxins and pathogens is critical for liver homeostasis. Retardation of liver proliferation was reported in hepatitis B virus (HBV) X protein (HBx)‐transgenic mice. However, the underlying mechanism of the HBx‐mediated disturbance of liver regeneration is unknown.

Genetic predisposition and environmental danger signals initiate chronic autoimmune hepatitis driven by CD4+ T cells

Matthias Hardtke‐Wolenski, Katja Fischer, Fatih Noyan, Jerome Schlue, Christine S. Falk, Maike Stahlhut, Norman Woller, Florian Kuehnel, Richard Taubert, Michael P. Manns, Elmar Jaeckel – 8 March 2013 – Autoimmune hepatitis (AIH) is defined as a chronic liver disease with loss of tolerance against liver tissue eventually leading to cirrhosis if left untreated. 80%‐90% of patients can be treated with a life‐long immunosuppression. Unfortunately, there are strong drug‐related side effects and steroid‐refractory patients.

Conversion from twice daily tacrolimus to once daily tacrolimus in long‐term stable liver transplant recipients: A single‐center experience with 394 patients

Jérôme Dumortier, Olivier Guillaud, Olivier Boillot – 8 March 2013 – After organ transplantation, strategies for simplifying the therapeutic regimen may improve adherence and prevent acute organ rejection and/or late graft loss. The aim of the present study was to evaluate the safety and efficacy of conversion from a tacrolimus (TAC) twice daily (bid) formulation to a once daily (qd) formulation in a large cohort of adult liver transplantation (LT) patients.

Subscribe to